Reactivation of hepatic EPO synthesis in mice after PHD loss.

Science
Yoji Andrew Minamishima, William G Kaelin

Abstract

The kidney controls erythropoietin production in adults, and the anemia that can accompany renal failure is a major medical problem. The liver controls erythropoietin production during fetal life but is silenced shortly after birth. Erythropoietin transcription is controlled by hypoxia-inducible factor (HIF), which is inhibited by three prolyl hydroxylases (PHD1, PHD2, and PHD3). Systemic PHD2 inactivation has been found to increase renal, but not hepatic, erythropoietin production. In contrast, we show here that simultaneous genetic inactivation of all three PHD paralogs in mice reactivates hepatic erythropoietin production and stimulates red blood synthesis, suggesting that pan-PHD inhibitory drugs might be useful for the treatment of anemia caused by chronic kidney disease.

References

Feb 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·V H HaaseR Jaenisch
Dec 24, 2005·Proceedings of the National Academy of Sciences of the United States of America·Michal SafranWilliam G Kaelin
May 24, 2008·Molecular Cell·William G Kaelin, Peter J Ratcliffe
Sep 2, 2009·Molecular and Cellular Biology·Yoji Andrew MinamishimaWilliam G Kaelin

❮ Previous
Next ❯

Citations

Sep 11, 2012·Langenbeck's Archives of Surgery·Martin MollenhauerMartin Schneider
May 5, 2012·American Journal of Nephrology·Tzvetanka BondevaGunter Wolf
Feb 9, 2012·American Journal of Respiratory Cell and Molecular Biology·Tanveer AhmadAnurag Agrawal
Nov 2, 2012·The Journal of Clinical Investigation·Qingdu LiuVolker H Haase
Aug 11, 2011·PloS One·Thilo WelschNathalia A Giese
Sep 3, 2013·Blood Cells, Molecules & Diseases·Xu ZhangVictor R Gordeuk
Feb 18, 2014·European Journal of Applied Physiology·Anne-Kristine Meinild LundbyCarsten Lundby
Oct 2, 2014·Nucleic Acid Therapeutics·Marc T AbramsDominique Stickens
Sep 22, 2012·High Altitude Medicine & Biology·Martha C Tissot van PatotAníbal J Llanos
Oct 1, 2015·Expert Opinion on Therapeutic Targets·Nicole RainvilleDon M Wojchowski
Mar 4, 2014·Expert Opinion on Biological Therapy·Lucia Del Vecchio, Francesco Locatelli
Dec 15, 2015·Nature Reviews. Nephrology·Patrick H Maxwell, Kai-Uwe Eckardt
Feb 20, 2016·Current Hypertension Reports·Farhanah Yousaf, Bruce Spinowitz
Jun 10, 2015·Journal of the American Society of Nephrology : JASN·Tomokazu SoumaNorio Suzuki
Sep 2, 2015·Proceedings of the National Academy of Sciences of the United States of America·Tomohiro SuharaYoji Andrew Minamishima
Nov 28, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·So Yeon Kim, Eun Gyeong Yang
Dec 12, 2012·Trends in Endocrinology and Metabolism : TEM·Yihai Cao
Mar 15, 2013·Kidney International·Toshio MiyataCharles van Ypersele de Strihou
Mar 16, 2013·Acta Physiologica·J Myllyharju
Oct 27, 2010·Annals of the New York Academy of Sciences·William G Kaelin
Mar 2, 2016·The Journal of Clinical Investigation·Navid M FarsijaniVolker H Haase
Jan 7, 2014·Gastroenterology·Yatrik M Shah, Liwei Xie
May 20, 2015·British Journal of Pharmacology·Terrance D BarrettMichael H Rabinowitz
Apr 15, 2015·Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology·Huijuan WangHuanling Wang
Jan 8, 2013·Blood Reviews·Volker H Haase
Jun 10, 2015·Nature Reviews. Nephrology·Mark J Koury, Volker H Haase
Apr 19, 2016·The Journal of Clinical Investigation·Hanako KobayashiVolker H Haase
May 26, 2012·Cell Cycle·Colleen WuAmato J Giaccia
Jun 5, 2013·Blood·Kristin FrankeBen Wielockx

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.